Trial of Cladribine and Low-Dose Cytarabine (LoDAC) Alternating With Decitabine vs. Hypomethylating Agents (HMA) Plus Venetoclax as Frontline Therapy for AML or High-Grade MDS in Patients Unfit for Intensive Induction
- Status
- WITHDRAWN
- Phase
- PHASE2
Clinical Trials Related to Cytarabine
Related studies linked through entity extraction aliases.
A Study of Revumenib in Combination With Chemotherapy for Patients Diagnosed With Relapsed or Refractory Leukemia
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
HEM-iSMART-B: Dasatinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological Malignancies
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
HEM-iSMART-C: Ruxolitinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological Malignancies
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
- Status
- RECRUITING
- Phase
- PHASE1
Selinexor in Combination With HAD or CAG Rregimens in Relapsed or Refractory Acute Myeloid Leukemia
- Status
- RECRUITING
- Phase
- PHASE3
A Study to Investigate Use of Off-the-shelf Natural Killer (NK) Cells (SAR445419) in Relapsed/Refractory Acute Myeloid Leukemia
- Status
- TERMINATED
- Phase
- PHASE1
Natural Killer(NK) Cell Therapy in r/r AML
- Status
- RECRUITING
- Phase
- PHASE1
Natural Killer (NK) Cell Therapy Targeting CD33 in Acute Myeloid Leukemia
- Status
- RECRUITING
- Phase
- PHASE1
Pediatric-inspired Regimen Combined With Venetoclax for Adolescent and Adult Patients With de Novo Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia
- Status
- RECRUITING
- Phase
- PHASE2
HEM iSMART-D: Trametinib + Dexamethasone + Chemotherapy in Children With Relapsed or Refractory Hematological Malignancies
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Study of Pedi-cRIB: Mini-Hyper-CVD With Condensed Rituximab, Inotuzumab Ozogamicin and Blinatumomab (cRIB) for Relapsed Therapy for Pediatric With B-Cell Lineage Acute Lymphocytic Leukemia
- Status
- RECRUITING
- Phase
- PHASE2
Testing the Use of Combination Therapy in Patients With Persistent Low Level Acute Myeloid Leukemia (AML) Following Initial Treatment
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
Natural Killer(NK) Cell Therapy for AML Minimal Residual Disease
- Status
- TERMINATED
- Phase
- PHASE1
Natural Killer(NK) Cell Therapy for Acute Myeloid Leukemia
- Status
- TERMINATED
- Phase
- PHASE1
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
- Status
- RECRUITING
- Phase
- PHASE2
Testing the Use of Combination Therapy in Patients With Persistent Low Level Acute Myeloid Leukemia Following Initial Treatment, The ERASE Study (A MyeloMATCH Treatment Trial)
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
Testing the Effects of Novel Therapeutics for Newly Diagnosed, Untreated Patients With High-Risk Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)
- Status
- RECRUITING
- Phase
- PHASE2
Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)
- Status
- RECRUITING
- Phase
- PHASE2
Etoposide+Cytarabine+PEG-rhG-CSF as First Line Mobilization Regimen of Hematopoietic Stem Cells in Patients With Hematological Malignancies
- Status
- RECRUITING
- Phase
- NA